AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
Portfolio Pulse from Vandana Singh
William Blair has upgraded AbbVie Inc (NYSE:ABBV) from Market Perform to Outperform, citing confidence in the company's growth prospects into 2024 despite competitive pressures. AbbVie's growth is attributed to strong performance by Skyrizi and Rinvoq, strategic acquisitions of ImmunoGen Inc (NASDAQ:IMGN) and Cerevel Therapeutics Holdings Inc (NASDAQ:CERE), and the highest dividend yield among peers. AbbVie faces competition for Humira, Imbruvica, and Botox but is expected to sustain growth. Q4 2023 earnings are anticipated on February 2, with an expected EPS of $2.81 and sales of $14.03 billion.
January 29, 2024 | 7:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie upgraded by William Blair to Outperform due to strong growth prospects and strategic acquisitions, with a positive outlook for 2024.
The upgrade by William Blair reflects a positive sentiment towards AbbVie's future performance, which could lead to increased investor confidence and a potential rise in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Cerevel Therapeutics' acquisition by AbbVie is part of AbbVie's strategy to strengthen its neuroscience pipeline, which may positively influence Cerevel's stock.
Cerevel's inclusion in AbbVie's strategic acquisitions suggests a positive outlook for the company's future, which could result in a short-term uptick in its stock price due to investor optimism.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 70
POSITIVE IMPACT
ImmunoGen's acquisition by AbbVie is seen as a strategic move to enhance AbbVie's pipeline, potentially impacting ImmunoGen's stock positively.
As a company acquired by AbbVie, ImmunoGen's stock may benefit from the association with a larger, growth-oriented pharmaceutical company, which could lead to a short-term increase in its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 70